ライフサイエンスコーパス: best-corrected visual acuity

1 optosis, but did not correct deficits in the best corrected visual acuity.

2 in the WFO group gaining 1 or more lines of best-corrected visual acuity.

3 tion and 16.0% (95% CI, 2.5%-29.4%) based on best-corrected visual acuity.

4 oroidal thickness [SFCT], phakic status, and best-corrected visual acuity.

5 d Early Treatment Diabetic Retinopathy Study best-corrected visual acuity.

6 set (aged </=3 years) visual loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/18

7 ifest refraction, uncorrected visual acuity, best-corrected visual acuity, 5% and 25% contrast best-c

8 tained: subjective and objective refraction, best-corrected visual acuity, accommodation, contrast se

9 Best-corrected visual acuity after Descemet's stripping

10 ary outcome measures were the mean change in best corrected visual acuity and adverse events.

11 Best-corrected visual acuity and central foveal thicknes

12 significant correlation was observed between best-corrected visual acuity and foveal retinal thicknes

13 ure at 6 days, rate of re-epithelialization, best-corrected visual acuity and infiltrate and/or scar

14 , there is a significant correlation between best-corrected visual acuity and myopia.

15 extensive ophthalmic examination, including best-corrected visual acuity and objective refraction, f

16 ariate analysis, after adjusting for initial best-corrected visual acuity and the antimicrobial treat

17 All eyes demonstrated improvement in best-corrected visual acuity and there was a 100% graft

18 corrected visual acuity, 5% and 25% contrast best-corrected visual acuity, and higher-order aberratio

19 ata collected included patient demographics, best-corrected visual acuity, and OCT features of vitreo

20 Graft survival, best-corrected visual acuity, and refractive error were

21 Demographic characteristics, best-corrected visual acuity, and smoking status were al

22 mass index, severity of visual field defect, best-corrected visual acuity, and STD on dark field cond

23 egression analyses adjusted for age, gender, best-corrected visual acuity, and test duration showed t

24 tening complications), nonpersistent loss of best-corrected visual acuity, and transient hypotony (re

25 ing clinical and anatomic outcome, including best-corrected visual acuity, and visual field indices w

26 d on assessment of new inflammatory lesions, best corrected visual acuity, anterior chamber cell grad

27 arly Treatment of Diabetic Retinopathy Study best-corrected visual acuity, applanation tonometry, sli

28 e primary outcome was defined as a change in best-corrected visual acuity at 52 weeks with a linear m

29 e at 3 years (r = -0.41; P = 0.02), and with best-corrected visual acuity at 6 months (r = -0.34; P =

30 Wavefront-guided eyes also achieved better best-corrected visual acuity at both the 5% and 25% cont

31 Best-corrected visual acuity at fluid resolution was not

32 The primary outcome measure was best-corrected visual acuity at the final visit.

33 Mean best corrected visual acuity (BCVA) (LogMAR +/- SEM) imp

34 Best corrected visual acuity (BCVA) and stereoacuity (St

35 Best corrected visual acuity (BCVA) at 6 weeks follow-up

36 h the group of normal volunteers for CFT and Best Corrected Visual Acuity (BCVA) at baseline and afte

37 09 and 31st of March 2010 and whose recorded best corrected visual acuity (BCVA) at DRSS fulfilled th

38 Mean distance Best corrected visual acuity (BCVA) at initial presentat

39 The progression of non-RRD resulted in best corrected visual acuity (BCVA) decrease from 0.8 to

40 Outcome measures included the mean change in best corrected visual acuity (BCVA) from baseline in the

41 analysis showed a significant improvement of best corrected visual acuity (BCVA) in the treated eye o

42 subfoveal choroidal neovascularisation, with best corrected visual acuity (BCVA) of 3/60-6/24 and 6/6

43 The final best corrected visual acuity (BCVA) of the left eye impr

44 LogMAR best corrected visual acuity (BCVA) was assessed preoper

45 Best corrected visual acuity (BCVA), central retinal thi

46 mplete ophthalmological evaluation including best corrected visual acuity (BCVA), IVCM (subepithelial

47 preoperative, early postoperative and final best corrected visual acuity (BCVA), rate of complicatio

48 (CMT on SD-OCT; mum) and the visual outcome (best corrected visual acuity (BCVA); logMAR), as follows

49 the secondary outcome was a 1-year change in best-corrected visual acuity (BCVA) (ETDRS chart).

50 jects were >/=65 years, had wet AMD, and had best-corrected visual acuity (BCVA) 10/200 to 20/80 in t

51 Best-corrected visual acuity (BCVA) 6 months after surge

52 was >/=2 line interocular difference in the best-corrected visual acuity (BCVA) and as bilateral if

53 Best-corrected visual acuity (BCVA) and center subfield

54 Postoperative best-corrected visual acuity (BCVA) and central corneal

55 cy end point of the study was mean change in best-corrected visual acuity (BCVA) and central foveal t

56 ab and thereafter monthly as needed based on best-corrected visual acuity (BCVA) and central foveal t

57 Best-corrected visual acuity (BCVA) and central retinal

58 Endpoints included best-corrected visual acuity (BCVA) and central retinal

59 o 3-6 months after the last implant included best-corrected visual acuity (BCVA) and central retinal

60 To investigate the relationship between best-corrected visual acuity (BCVA) and central retinal

61 Mean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield

62 re assessed, as were the predictors of final best-corrected visual acuity (BCVA) and change in BCVA.

63 Best-corrected visual acuity (BCVA) and CST were measure

64 ithm of minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) and evolution of mor

65 The main outcome measures were best-corrected visual acuity (BCVA) and injection freque

66 The main outcome measures included logMAR best-corrected visual acuity (BCVA) and macular microstr

67 ay 0 to month 2), followed by individualized best-corrected visual acuity (BCVA) and optical coherenc

68 and second outcomes were reoperation rates, best-corrected visual acuity (BCVA) and postoperative co

69 ospective comparative-effectiveness study of best-corrected visual acuity (BCVA) and refractive error

70 The main outcomes measured were final best-corrected visual acuity (BCVA) and surgical complic

71 To estimate the yearly rate of change of best-corrected visual acuity (BCVA) and the risk of loss

72 d between eyes that recovered >/=20/20 final best-corrected visual acuity (BCVA) and those with <20/2

73 Mean best-corrected visual acuity (BCVA) and Visual Function

74 The main outcome measure studied was final best-corrected visual acuity (BCVA) as dependent on the

75 eek treatment period for safety assessments, best-corrected visual acuity (BCVA) assessment by Early

76 aseline and annual eye examinations included best-corrected visual acuity (BCVA) assessments, slit-la

77 IOP) rise was correlated with improvement in best-corrected visual acuity (BCVA) at 1 and 6 months.

78 categorized into 3 groups based on change in best-corrected visual acuity (BCVA) at 3 months (logMAR

79 Visual outcome measures included best-corrected visual acuity (BCVA) at 4 m and 0.4 m, ga

80 The primary outcome was best-corrected visual acuity (BCVA) at 6 months follow-u

81 visual improvement was associated with lower best-corrected visual acuity (BCVA) at baseline (P = .00

82 ure at month 6, and categoric improvement in best-corrected visual acuity (BCVA) at month 6.

83 usion status, intraocular pressure (IOP) and best-corrected visual acuity (BCVA) at presentation.

84 primary outcome was change in amblyopic eye best-corrected visual acuity (BCVA) at the 2-week visit.

85 s administered before aflibercept injection, best-corrected visual acuity (BCVA) before and after afl

86 include comparing mean macular thickness and best-corrected visual acuity (BCVA) between those who de

87 baseline retinal morphologic parameters and best-corrected visual acuity (BCVA) change (structure-fu

88 : 5 letters at a 1-sided alpha level 0.1) in best-corrected visual acuity (BCVA) change from baseline

89 Mean best-corrected visual acuity (BCVA) change from baseline

90 atients with prior anti-VEGF treatment, mean best-corrected visual acuity (BCVA) changes from baselin

91 mplete ophthalmologic examination, including best-corrected visual acuity (BCVA) determination and fu

92 ons, including measurement of presenting and best-corrected visual acuity (BCVA) for distance using t

93 Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) from 20/32 to 20/500

94 ry efficacy end point was the mean change in best-corrected visual acuity (BCVA) from baseline at mon

95 The primary endpoint is the mean change in best-corrected visual acuity (BCVA) from baseline to 24

96 Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to mon

97 ion of patients who gained >/= 15 letters in best-corrected visual acuity (BCVA) from baseline to wee

98 Two weeks later best-corrected visual acuity (BCVA) improved up to 20/25

99 cataract surgery and the patients (%) with a best-corrected visual acuity (BCVA) improvement of >/=15

100 retinal inner layers (DRIL) is predictive of best-corrected visual acuity (BCVA) in retinal vein occl

101 The primary outcome measure is the change in best-corrected visual acuity (BCVA) in the study eye fro

102 ntage of eyes with improvement from baseline best-corrected visual acuity (BCVA) letter score >/=15 a

103 Mean best-corrected visual acuity (BCVA) letter score change,

104 Improvement in best-corrected visual acuity (BCVA) measured as the prop

105 Best-corrected visual acuity (BCVA) measured by a modifi

106 mplete ophthalmologic examination, including best-corrected visual acuity (BCVA) measurement on Early

107 mplete ophthalmologic examination, including best-corrected visual acuity (BCVA) measurement on ETDRS

108 The primary outcome was 1-year gain in best-corrected visual acuity (BCVA) of >/=15 letters.

109 VI was defined as post-refraction binocular best-corrected visual acuity (BCVA) of </= 20/30.

110 All had best-corrected visual acuity (BCVA) of 20/20, no dry eye

111 lusion criteria included presence of VMA and best-corrected visual acuity (BCVA) of 20/32 or worse in

112 ntrolled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34-68 Early Treat

113 (range, 239-727 mum) and a mean preinjection best-corrected visual acuity (BCVA) of 63 approximated E

114 After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to

115 Participants underwent best-corrected visual acuity (BCVA) testing, ophthalmosc

116 Mean preoperative best-corrected visual acuity (BCVA) was 1.11+/-0.59 loga

117 The mean preoperative best-corrected visual acuity (BCVA) was 1.39+/-0.64 loga

118 nimum angle of resolution (logMAR) (Snellen) best-corrected visual acuity (BCVA) was 1.81+/-0.56 (20/

119 Baseline best-corrected visual acuity (BCVA) was 20/125 in both e

120 Median best-corrected visual acuity (BCVA) was 20/30 at present

121 Mean best-corrected visual acuity (BCVA) was 20/32 (median 20

122 Preoperative best-corrected visual acuity (BCVA) was 20/40 or worse i

123 Best-corrected visual acuity (BCVA) was 3/10 in his righ

124 ce between the median preoperative and final best-corrected visual acuity (BCVA) was assessed and the

125 Baseline best-corrected visual acuity (BCVA) was better in LCS co

126 the occlusion occurred within 12 months and best-corrected visual acuity (BCVA) was between </=73 an

127 Baseline best-corrected visual acuity (BCVA) was between 0.3 and

128 Best-corrected visual acuity (BCVA) was compared between

129 Mean change from baseline best-corrected visual acuity (BCVA) was determined at we

130 Best-corrected visual acuity (BCVA) was determined by ce

131 Best-corrected visual acuity (BCVA) was measured 30 to 9

132 At monthly intervals, best-corrected visual acuity (BCVA) was measured and ret

133 by time-domain optical coherence tomography, best-corrected visual acuity (BCVA) was measured by Earl

134 Lesion size assessments and best-corrected visual acuity (BCVA) were conducted at sc

135 Preoperative, annual, and last distance best-corrected visual acuity (BCVA) were obtained retros

136 of the minimal angle of resolution (logMAR) best-corrected visual acuity (BCVA) were recorded and an

137 There was an increase in mean best-corrected visual acuity (BCVA) with IVT-AFL 2q8 ove

138 ator on optical coherence tomography or when best-corrected visual acuity (BCVA) worsened by >/=5 Ear

139 Furthermore, best-corrected visual acuity (BCVA), age, and retinal pi

140 al uncorrected visual acuity (UCVA), decimal best-corrected visual acuity (BCVA), and average keratom

141 th, final status of Descemet membrane, final best-corrected visual acuity (BCVA), and incidence of po

142 omain optical coherence tomography (SD-OCT), best-corrected visual acuity (BCVA), and microperimetry.

143 p between axial length and closure rate, the best-corrected visual acuity (BCVA), and the surgical co

144 At each study visit, measurements of CVP, best-corrected visual acuity (BCVA), area of CNP, retina

145 Best-corrected visual acuity (BCVA), central foveal thic

146 moglobin A1c (HbA1c), body mass index (BMI), best-corrected visual acuity (BCVA), central subfield th

147 Secondary outcomes included mean change in best-corrected visual acuity (BCVA), change in central m

148 of change in CNV surface area with change in best-corrected visual acuity (BCVA), change in central m

149 mologic examinations including assessment of best-corrected visual acuity (BCVA), contrast sensitivit

150 DE questionnaires, age, duration of disease, best-corrected visual acuity (BCVA), corneal fluorescein

151 The re-DMEK eyes were evaluated for best-corrected visual acuity (BCVA), densitometry, endot

152 Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell de

153 Best-corrected visual acuity (BCVA), endothelial cell de

154 The main outcome measures were postoperative best-corrected visual acuity (BCVA), endothelial cell de

155 At each study visit best-corrected visual acuity (BCVA), FAF, and SD OCT ima

156 Review of charts and photographs comprised best-corrected visual acuity (BCVA), foveal center field

157 MainOutcome Measures: Clinical presentation, best-corrected visual acuity (BCVA), fundus abnormalitie

158 subdivided into classic stages and underwent best-corrected visual acuity (BCVA), fundus autofluoresc

159 Change of best-corrected visual acuity (BCVA), intraocular pressur

160 Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), intraocular pressur

161 Change in mean best-corrected visual acuity (BCVA), mean central retina

162 Best-corrected visual acuity (BCVA), moderate visual los

163 demographics, preoperative and postoperative best-corrected visual acuity (BCVA), nuclear density, ex

164 Best-corrected visual acuity (BCVA), number of anti-VEGF

165 at onset, medical history, initial symptoms, best-corrected visual acuity (BCVA), ophthalmoscopy, fun

166 Outcome measures included best-corrected visual acuity (BCVA), postoperative fovea

167 Main outcome measures were best-corrected visual acuity (BCVA), presence of retinal

168 Improvement in best-corrected visual acuity (BCVA), resolution of subre

169 The parameters evaluated were the best-corrected visual acuity (BCVA), Schirmer test, tear

170 ratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry ce

171 Best-corrected visual acuity (BCVA), tear osmolarity, th

172 re included, and images were correlated with best-corrected visual acuity (BCVA), widefield angiograp

173 creased contrast sensitivity, even with good best-corrected visual acuity (BCVA).

174 radiation retinopathy, optic neuropathy, and best-corrected visual acuity (BCVA).

175 recurrence of macular edema or a decrease in best-corrected visual acuity (BCVA).

176 Ocular surface stability, best-corrected visual acuity (BCVA).

177 n of a relationship between FAF patterns and best-corrected visual acuity (BCVA).

178 erative complications, device retention, and best-corrected visual acuity (BCVA).

179 ubjects with retinal reattachment had better best-corrected visual acuity (BCVA; mean BCVA, 1.22+/-0.

180 Best-corrected visual acuity (BCVA; Snellen's charts), O

181 cluded in the analysis for early responders (best-corrected visual acuity [BCVA] obtained at baseline

182 The preoperative and postoperative best-corrected visual acuities (BCVAs) were compared as

183 detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), and recurrence r

184 Inclusion criteria were best-corrected visual acuity between 20/20 and 20/25, sp

185 ncluding assessment of refractive errors and best-corrected visual acuity, biomicroscopy, color fundu

186 Best-corrected visual acuity (BVCA), LLVA, and microperi

187 Black on White Best Corrected Visual Acuity (BW-BCVA), White on Black B

188 Main outcome measures included best-corrected visual acuity, central retinal thickness,

189 Outcomes included best-corrected visual acuity, central subfield thickness

190 cuity response (mean change from baseline in best-corrected visual acuity [CFB BCVA]; categorized imp

191 Average best-corrected visual acuity change from baseline ranged

192 Best-corrected visual acuity changed by -0.2 letters in

193 Other outcome measures included best-corrected visual acuity, complications, and hyperte

194 e month before cataract surgery, we assessed best-corrected visual acuity, contrast sensitivity, stra

195 Best-corrected visual acuity correlated significantly wi

196 mologic examinations included cover testing, best corrected visual acuity, cycloplegic objective refr

197 es), 326 (90.6%) completed the study (5-year best-corrected visual acuity data available for 415 eyes

198 ter a mean follow-up of 27 +/- 8 months, the best-corrected visual acuity decreased from 1.3 preopera

199 modified intention-to-treat population (mean best corrected visual acuity difference 3.9 letters [95%

200 Because best-corrected visual acuity does not correspond directl

201 Best-corrected visual acuity, endothelial cell density,

202 ss and visual impairment are widely based on best-corrected visual acuity excluding uncorrected refra

203 e found an improvement in mean (SD [95% CI]) best-corrected visual acuity from 0.66 (0.71 [0.30-1.02]

204 There was a significant improvement in best-corrected visual acuity from a mean of 0.65 LogMAR

205 There was an overall improvement in best-corrected visual acuity from a mean preoperative lo

206 endpoints were the change in mean and median best-corrected visual acuity from baseline at years 1 an

207 Best-corrected visual acuity, fundus photographs, and sp

208 ecrease >/= 50 mum) and functional response (best-corrected visual acuity gain >/= 1 line) were asses

209 horoidal thickness) for functional response (best-corrected visual acuity gain >/=2 lines) were asses

210 met its main objective, demonstrating a mean best-corrected visual acuity gain of 8.3 letters (mean 6

211 advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 le

212 Best-corrected visual acuity gains achieved during VISTA

213 ge group, males, literates, service holders, best corrected visual acuity >0.3 LogMAR, were each sign

214 In seven cases, the mean best-corrected visual acuity improved after foveal reatt

215 Mean logMAR best-corrected visual acuity improved from 0.67 +/- 0.53

216 Mean best-corrected visual acuity improved from 1.08 +/- 0.65

217 Best-corrected visual acuity improved from an average of

218 Following the first implantation, average best-corrected visual acuity improved significantly from

219 Final mean best-corrected visual acuity in all cases was 20/35 (ran

220 s with primary open-angle glaucoma who had a best-corrected visual acuity in the better eye equal to

221 million people in the United States had VI (best-corrected visual acuity in the better-seeing eye),

222 The patient's best-corrected visual acuity in the right eye was 20/70

223 Primary outcome was change from baseline in best-corrected visual acuity in uveitic eyes (5 letters

224 up, including preoperative and postoperative best-corrected visual acuity, incidence of macular edema

225 ical indices correlated with transient worse best-corrected visual acuity, including presence of cata

226 Best-corrected visual acuity, Indian Vision Function Que

227 All patients had preserved best-corrected visual acuity into adulthood, with a mean

228 ophthalmological examination, including the best corrected visual acuity, intraocular pressure measu

229 an exhaustive ophthalmological examination (best-corrected visual acuity, intraocular pressure, biom

230 Best-corrected visual acuity letter score gain of 15 let

231 nation including medical and ocular history, best-corrected visual acuity, limbal anterior chamber de

232 Best-corrected visual acuity, LLVA, and central retinal

233 Median BCVA (best-corrected visual acuity, logMAR) was 0.1 in the MFS

234 In the proband, best-corrected visual acuity (</=0.7 logMAR) was stable

235 Postoperative mean best-corrected visual acuity measured 0.14+/-0.26 logari

236 Every 4 weeks, participants underwent best-corrected visual acuity measurement, fundus examina

237 Best-corrected visual acuity, monitored as part of the s

238 Improvements in best-corrected visual acuity obtained from the literatur

239 res included patient demographics, symptoms, best-corrected visual acuity, ocular surface stability,

240 man presented as an emergency in the UK with best corrected visual acuities of 1/60 OD and 6/18 OS, b

241 als aged 3 years or older with, in each eye, best corrected visual acuity of 20/60 or worse, or visua

242 A mean postoperative best corrected visual acuity of 63 +/- 30 ETDRS letters

243 t had experienced at least 1 RD, achieving a best-corrected visual acuity of >/=20/40 compared to 53%

244 nce interval, 16-38) at 5 years, with a mean best-corrected visual acuity of 1.13 (logarithm of the m

245 The healthy subjects had best-corrected visual acuity of 20/20 or better with no

246 among 12 patients with visual impairment and best-corrected visual acuity of 20/200 or worse in their

247 The percentage of eyes with a preoperative best-corrected visual acuity of 20/200 or worse varied f

248 Overall, 51 eyes (35%) attained a final best-corrected visual acuity of 20/40 (0.3 logarithm of

249 whereas only 2 eyes (8.7%) attained a final best-corrected visual acuity of 20/40 (0.3 logarithm of

250 last follow-up, 6 of 19 patients (31.6%) had best-corrected visual acuity of 20/400 or better.

251 patient age was 34.2 (14.7) years, mean (SD) best-corrected visual acuity of all eyes was 47.8 (16.9)

252 nd 11 eyes with low MS (<6 dB) but very good best-corrected visual acuity of at least 72 Early Treatm

253 at onset, medical history, initial symptoms, best-corrected visual acuity, ophthalmoscopy, fundus pho

254 months; >98% of all subjects achieved 20/40 best-corrected visual acuity or better.

255 No changes in best-corrected visual acuity or low luminance visual acu

256 ths to 21.5 years) reported deterioration in best-corrected visual acuity over time.

257 nd 52 weeks, having excluded fluctuations in best corrected visual acuity owing to vitreous haemorrha

258 ted eyes, there was no significant change in best-corrected visual acuity (P = .098), central foveal

259 ns, cycloplegic refractions, uncorrected and best-corrected visual acuities, power vector of astigmat

260 ensity in the SRL negatively correlated with best-corrected visual acuity (r = -0.28; P = .05) and se

261 ns (R(2) = 0.031; P = .327) or to changes in best-corrected visual acuity (R(2) = 0.017; P = .470) or

262 Best-corrected visual acuity ranged from 20/20 to 20/30.

263 Preoperative best-corrected visual acuity ranged from HM to 0.15 whil

264 reoperative and postoperative data including best corrected visual acuity recorded in LogMAR units, s

265 Best-corrected visual acuity recorded before surgery ran

266 Patients were tested for best-corrected visual acuity, recurrence-free survival,

267 -related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in

268 e main outcome measure was the difference in best-corrected visual acuity scores between baseline and

269 Best-corrected visual acuity, slit-lamp biomicroscopy, d

270 amination, including medical history review, best-corrected visual acuity, slitlamp biomicroscopy, in

271 ants underwent an ophthalmologic assessment (best-corrected visual acuity, stereoacuity, cycloplegic

272 The best corrected visual acuity, surface defects and cornea

273 He underwent the following tests: best corrected visual acuity, tear osmolarity, tear film

274 n origin, and responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on

275 improved from a mean (SD) of 2.5 (1.6) using best-corrected visual acuity to 9.5 (0.5) using the port

276 d RIDE/RISE, the proportion of patients with best-corrected visual acuity typically required for an u

277 Improvement in best-corrected visual acuity using an automated Snellen

278 tial and follow-up visits included recording best-corrected visual acuity (VA) using the Snellen VA c

279 Best-corrected visual acuity (VA), complications, resolu

280 atment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (VA).

281 Her best corrected visual acuity was 20/50 in the right eye

282 Postoperative best corrected visual acuity was determined in both eyes

283 The mean best-corrected visual acuity was 0.800 logMAR (interquar

284 On the final follow-up visit, mean best-corrected visual acuity was 20/125 (range, 20/25-20

285 Mean best-corrected visual acuity was 20/144 (range, 20/25-20

286 The mean best-corrected visual acuity was 20/22 (range, 20/20-20/

287 Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16

288 (mean of 13.7 months + 6.5), improvement of best-corrected visual acuity was achieved in 22 (91.7%)

289 Best-corrected visual acuity was improved in 13 eyes (81

290 Best-corrected visual acuity was measured at annual stud

291 Best-corrected visual acuity was measured using the Earl

292 cted Visual Acuity (BW-BCVA), White on Black Best Corrected Visual Acuity (WB-BCVA), Mars Contrast Se

293 At 1 year, >/=10- and >/=15-letter gains in best-corrected visual acuity were observed in 34.5% (10/

294 change in vitreous haze grade, and change in best corrected visual acuity) were significantly better

295 Eyes undergoing both treatments had improved best-corrected visual acuity (WFG: mean, 0.05 [95% CI, 0

296 There was no association of the best-corrected visual acuity with any choroidal morpholo

297 s' functionality in 3 scenarios: using their best-corrected visual acuity with no low-vision aids, us

298 Changes in best-corrected visual acuity with RTH258 were comparable

299 The prevalence of visual impairment (best-corrected visual acuity worse than 20/40 in the bet

300 by biomicroscopy judged to be the cause of a best-corrected visual acuity worse than 20/40.